Performance status-1 - Slightly symptomatic Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Evaluating a new CAR-T cell therapy for patients with relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects.   Some background MM is a type of cancer of the...

Read More

SBRT vs. radiotherapy in patients with inoperable non-small cell lung cancer

Posted by on Mar 5, 2019 in Lung cancer | 0 comments

In a nutshell This study determined whether stereotactic body radiation therapy (SBRT) was more effective than standard radiotherapy in patients with inoperable non-small cell lung cancer. The study found that SBRT led to better survival outcomes for these patients, with minimal side effects. Some background Tumor removal by surgery is the standard of...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

The socioeconomic impact of cachexia in elderly patients with advanced lung cancer

Posted by on Apr 9, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the impact of cachexia (weakness or wasting of the body) in elderly patients with advanced non-small-cell lung cancer on disability, hospitalization and medical costs. The authors concluded that patients with cachexia had a higher risk of disability, longer hospital stays and higher medical costs, while being treated...

Read More

Treatment that activates the immune system to kill tumors in extensive-stage small cell lung cancer

Posted by on Sep 4, 2017 in Lung cancer | 0 comments

In a nutshell This trial looked at therapy that activates the immune system to kill cancerous tumors in patients with extensive stage small cell lung cancer (ES-CLC). The authors concluded pembrolizumab (Keytruda) is tolerable and a promising treatment for patients with heavily treated ES-SCLC. Some background Extensive-stage small cell lung...

Read More

Altering drug dosage during chemotherapy can decrease toxic side effects for patients with NSCLC

Posted by on Apr 15, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined whether altering the recommended dose of chemotherapy drugs during treatment was beneficial to patients. This trial concluded that altering doses of paclitaxel (Taxol) during chemotherapy could be beneficial to reduce neuropathy in patients with advanced non-small-cell lung cancer.      Some...

Read More

A comparison of how FEC120 treatment vs EC-docetaxel treatment affect survival in patients with node-positive primary breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study compared the side effects and outcome of two drug regimens in women with high-risk node-positive breast cancer (BC). Both treatment regimens were found to have similar survival outcomes. Some background Standard treatment in node positive BC (cancer that has spread to the lymph nodes) consists of two categories of...

Read More

The impact of exercise on the risk of cardiovascular events in women with non-metastatic breast cancer

Posted by on Mar 20, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated whether exercise was associated with a reduction in the risk of cardiovascular disease (CVD) in patients with non-metastatic breast cancer (BC). Exercise was found to be linked to a significant reduction in the risk of CVD for this patient group. Some background CVD is a leading cause of death among women with...

Read More

Incidence of ovarian function recovery in women over 40 with chemotherapy induced amenorrhea

Posted by on Mar 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy.  Some...

Read More